Category: Headlines

The merger of South Korean shipbuilders HD Hyundai Heavy Industries and HD Hyundai Mipo has been approved by shareholders, paving the way for the launch of the combined company, HD Hyundai Heavy Industries, on December 1. The merger plan passed with 98.54 per cent and 87.56 per cent approval respectively from shareholders attending the extraordinary general meetings of each company on October 23. Both companies announced their intention to merge in August, with aims to secure advanced technologies, and expand their market presence, among others. South Korea’s Fair Trade Commission approved the merger in September, determining it would not impact competition as it was between affiliates. The integrated company anticipates the merger will significantly enhance its competitiveness, particularly in the defence sector. The company plans to expand its defence market offering and increase orders for special-purpose vessels by combining HD Hyundai Heavy Industries’ naval shipbuilding expertise with HD Hyundai Mipo’s facilities and resources. It added that it also aims to integrate research and development capabilities to reduce development risks and costs and respond faster to environmental regulations. The combined entity plans to achieve sales of KRW37 trillion ($26.8 billion) by 2035, including KRW10 trillion in the defence sector, nearly doubling the KRW19 trillion recorded in 2024. An HD Hyundai Heavy Industries official stated, “Shareholders have also recognized the necessity and strategic effectiveness of this merger.” Source: https://www.bairdmaritime.com/shipbuilding/shareholders-approve-merger-of-hd-hyundai-heavy-and-hd-hyundai-mipo

Life sciences group Thermo Fisher has sealed an all-cash takeover of drug trial software maker Clario in a deal that values the technology group at up to $9.4bn. The acquisition gives Thermo Fisher access to a platform that is playing a critical role in managing the clinical data essential to drug trials. Clario’s software has been deployed across 26,000 trials playing a role in 70 per cent of US drug approvals. As part of the deal, Thermo Fisher will pay Clario’s private equity owners just under $8.9bn upfront in cash and an additional $525mn, largely dependent on performance milestones being hit, the Massachusetts-based life sciences group said on Wednesday. The deal is one of the biggest full private equity exits of the year, generating a huge payday for Clario’s co-controlling investors Stockholm-based private equity group Nordic Capital and Luxembourg-based Astorg Partners, which created it from a merger of two software companies in 2021. The Financial Times first reported that Thermo Fisher was nearing a deal on Tuesday. As drug trials increase in complexity and the number reach an all-time high, driven by a surge in innovation, the acquisition of Clario will allow Thermo Fisher to better serve its pharmaceutical and biotech client base with a platform that provides data essential to the regulatory approval process. Thermo Fisher has historically been an active acquirer but it has focused on smaller deals in recent years. The deal is Thermo Fisher’s biggest acquisition since 2021 when it bought contract research organisation PPD in a deal worth $17.4bn. Marc Casper, Thermo Fisher’s longtime chief executive, said Clario was “very complementary to what we do today” and would increase the life sciences group’s “large presence in software that serves our biopharma customers”. Underpinning the deal was “the digital transformation that’s going on in clinical research using these technologies and software to streamline the drug approval process”, said Casper. Clario’s platform “ultimately means better returns for pharma companies and more innovative medicines for patients”, he added. The deal, which is expected to close by the middle of next year, is a big coup for Clario’s private equity backers. Until recently they had been considering a public listing for the group in a dealmaking market where sponsors are struggling to exit assets. Clario’s current owners Nordic and Astorg oversee €34bn and €23bn of assets under management, respectively. Clario also counted Novo Holdings and Cinven as minority investors. In 2022, Nordic sold medical diagnostics group The Binding Site to Thermo Fisher for $2.6bn. The acquisition comes amid a volatile period for Thermo Fisher and the wider healthcare sector. Shares in Thermo Fisher dropped earlier this year as investors fretted over the impact of US President Donald Trump’s cuts to the National Institutes of Health on its sales, but they have since rallied. Thermo Fisher shares are up 6 per cent this year, giving it a market capitalisation of $210bn, as of Tuesday’s close. WilmerHale provided legal counsel to Thermo Fisher, while Evercore and Latham & Watkins advised Clario. Source: https://www.ft.com/content/2d12fd44-dd56-4c77-a9b8-ca20c277bb66

In a significant development for the pharmaceutical industry, the Competition Commission of India (CCI) has given its approval for Torrent Pharmaceuticals’ proposed acquisition of J B Chemicals and Pharmaceuticals . This decision marks a crucial step forward in the consolidation process within the Indian pharma sector. Implications of the DecisionThe CCI’s green light for this takeover is noteworthy, as it comes with certain conditions attached to the transaction. While the specific details of these conditions have not been disclosed, such stipulations are typically aimed at ensuring fair competition in the market and preventing any potential monopolistic practices. Industry ImpactThis acquisition could potentially reshape the competitive landscape in the Indian pharmaceutical industry. Torrent Pharma, already a significant player in the market, stands to strengthen its position further with the addition of J B Chemicals and Pharmaceuticals to its portfolio. Next StepsWith the CCI’s conditional approval in place, the next phase will likely involve Torrent Pharmaceuticals and J B Chemicals and Pharmaceuticals working towards meeting the stipulated conditions. The companies will need to navigate these requirements carefully to successfully complete the acquisition process. As this story develops, stakeholders in the pharmaceutical industry will be keenly watching how this merger unfolds and its potential impact on market dynamics, product offerings, and competitive strategies in the sector. Source:https://scanx.trade/stock-market-news/corporate-actions/torrent-pharmaceuticals-issues-corrigendum-for-6-842-80-crore-open-offer-to-j-b-chemicals-shareholders/18531257

Samsung Electronics finalizes Xealth acquisition for digital health app Xealth’s platform permits physicians and care teams to order, deliver and monitor digital health tools from the EHR. Consumer electronics giant Samsung Electronics announced that it has concluded its acquisition of Xealth, a digital health prescription platform that helps doctors prescribe digital health apps. Samsung signed an agreement to acquire Xealth back in July. Xealth will continue its operations under its existing brand, and its leadership team will remain in place. Xealth integrates digital health offerings into the clinical workflow, allowing health systems to improve patient care and drive clinical efficiency. According to the company, the offerings include multimedia patient education, digital clinical assessments, remote patient monitoring programs, virtual care referrals and other ancillary services that help prepare, assess and support patients before, during and between appointments. Xealth’s Digital Care SMART on FHIR app allows physicians and care teams to order, deliver and monitor digital health tools from the EHR, with clinical decision support that matches patients to pertinent answers. The app can be downloaded from the EHR’s app stores and configured by the health system team to launch directly in the provider’s charting workflow. According to the company, the integration provides Xealth the ability to leverage data in the EHR to suggest and automatically enroll patients into various programs. “Samsung and the Xealth team will engage, learn and support health systems, consumers and digital health partners in creating a healthcare ecosystem that aims to improve the health of everyone,” Dr. Hon Pak, senior vice president and head of digital health team, mobile eXperience business of Samsung Electronics, said in a statement. ​​Mike McSherry, CEO and cofounder of Xealth, asserted that the company’s mission is to reinforce the bond between medical care teams and their patients through familiar technologies. “That driving force is supported and propelled through Samsung in a way that will bring truly connected care and add fresh context to the patient experience in a way not possible before,” McSherry said in a statement. “Together with Samsung and our network of healthcare leaders, we will design a bridge between home health monitoring and clinical decision-making, with provider workflows and the patient-provider relationship at the core.” THE LARGER TREND In 2024, South Korean-based medical AI provider Lunit signed a three-year supply contract with Samsung Electronics. The deal was for the integration of Lunit’s two chest X-ray AI solutions, Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage, into Samsung’s line of premium X-ray devices. The AI-integrated X-ray devices were initially rolled out in the United States, Canada and Europe. In 2021, AI developer VUNO closed a deal with Samsung Electronics to incorporate its AI-enabled chest X-ray diagnostic solution with Samsung’s premium mobile digital radiograph system. VUNO’s Med Chest X-ray, which was added to Samsung’s mobile digital radiograph system, was also integrated into its GC85A premium ceiling type digital radiography system The deal allowed Samsung Electronics to provide an advanced system that integrates AI technology into its key premium X-ray devices. In March, Xealth announced a strategic investment from Morningside Ventures. The funding was used to boost Morningside’s digital health portfolio and expand Xealth’s footprint within health systems by helping them to manage and deploy their digital health formularies more effectively. In 2024, Xealth announced that the Froedtert & The Medical College of Wisconsin (MCW) health network leveraged its digital health platform to engage select patient populations with Season Health, a clinical nutrition provider. Via Xealth’s digital health platform, the Froedtert & MCW offered Season Health’s scalable, clinically driven nutrition services to employee and patient populations, with a focus on patients with diabetes. The collaboration aims to improve clinical outcomes by integrating nutrition as a crucial element of chronic condition care. Source: https://www.mobihealthnews.com/news/samsung-electronics-finalizes-xealth-acquisition-digital-health-app

Hino Motors, a truck unit of Toyota Motor, alongside Daimler Truck subsidiary Mitsubishi Fuso Truck and Bus, have outlined plans to consolidate their production facilities in Japan. The move is a preparatory step towards their planned merger and the formation of a new holding company, Archion. The consolidation process will reduce the number of domestic truck production sites from five to three, with operations focusing on the Kawasaki Plant in Kanagawa Prefecture, the Koga Plant in Ibaraki Prefecture, and the Nitta Plant in Gunma Prefecture. As part of this restructuring, Mitsubishi Fuso will shutter its Nakatsu plant in Aikawa, and Hino will transition its Hamura plant in Tokyo to Toyota. Joint investments in next-generation technologies are also on the agenda for Hino and Mitsubishi Fuso, with backing from Toyota and Daimler Truck, each securing a 25% stake in Archion. The integration of operations under Archion is expected to be completed by April. Archion’s leadership has been confirmed, with Karl Deppen of Mitsubishi Fuso set to take on the role of CEO. Hetal Laligi will step in as CFO, and Satoshi Ogiso, currently president of Hino Motors, will become the chief technology officer. Deppen said: “With the strong brands Fuso and Hino, we will provide superior products and solutions for our customers and their needs. Archion will implement an effective governance model to build trust by promoting transparency, compliance and improving financial performance.” The merger is set to leverage Hino’s medium- and heavy-duty truck expertise with Mitsubishi Fuso’s focus on light-duty vehicles. The aim is to create a synergy that will lead to more competitive products, cost-efficient operations, and quicker time-to-market for new launches. The companies intend to reallocate savings from integration and improved efficiencies towards investments in the CASE domain (Connected/Autonomous & Automated/Shared/Electric). Additionally, Archion plans to develop a range of products across all zero-emission vehicle (ZEV) segments, drawing on the technological prowess and scale of the Toyota and Daimler Truck network. Ogiso commented: “By combining the strengths of all four companies, we will accelerate the development of CASE technologies and shape the future of commercial mobility. To achieve this, we will foster a corporate culture that values mutual learning and respects diversity.” Source: https://www.just-auto.com/news/hino-motors-mitsubishi-fuso-japan/?cf-view

The transaction will see Toro shareholders gain exposure to IsoEnergy’s growing uranium portfolio in Canada and the United States. IsoEnergy (TSX:ISO,NYSE American:ISOU) is set to acquire Australia’s Toro Energy (ASX:TOE,OTC Pink:TOEYF) in an all-share deal that will consolidate two uranium developers into a single diversified platform as global nuclear demand surges and uranium prices continue to strengthen. The merger brings Toro’s 100 percent-owned Wiluna uranium project in Western Australia into IsoEnergy’s development pipeline, adding a large, scoping-stage asset to the company’s holdings that already include the high-grade Hurricane deposit in Canada’s Athabasca Basin and several past-producing US mines. Once combined, the pro forma company will hold total measured and indicated resources of 55.2 million pounds U3O8 and inferred resources of 4.9 million pounds. “The Wiluna uranium project strengthens our portfolio with a large, previously permitted asset in a top-tier jurisdiction at a time when global nuclear demand is accelerating,” said Philip Williams, IsoEnergy’s CEO and Director. Toro’s Wiluna project, which comprises the Centipede-Millipede, Lake Way, and Lake Maitland deposits, sits about 30 kilometers south of the town of Wiluna and represents one of Western Australia’s most advanced undeveloped uranium assets. The merger will also broaden IsoEnergy’s presence in Australia, which ranks first globally in uranium resources and was among the top five producers in 2024. Toro Executive Chairman Richard Homsany said the deal provides Toro shareholders the opportunity to be part of a larger, leading uranium company listed on the TSX and NYSE. Following the transaction, Toro shareholders will hold about 7.1 percent of IsoEnergy’s fully diluted shares and will gain indirect exposure to IsoEnergy’s assets in Canada and the US, including the Hurricane deposit in Saskatchewan and the company’s Utah-based projects. The merger comes amid a uranium market revival driven by renewed global interest in nuclear power as a clean energy source. The World Nuclear Association’s 2025 Fuel Report projects uranium demand to rise by roughly 30 percent by 2030 and to more than double by 2040, as nations expand reactor fleets to meet decarbonization goals. Pending approval of the scheme by Toro shareholders, expected in early 2026, the Australian company will be delisted from the ASX, while IsoEnergy’s shares will continue trading on the NYSE American and TSX. The company noted that an eventual ASX listing for IsoEnergy may be considered but is not a condition of the transaction. In a separate announcement last month, IsoEnergy also launched its 2025 US exploration program focused on its uranium projects in southeast Utah. The initiative includes drilling ten rotary holes totaling 15,000 feet at the Flatiron claims near the historic Tony M mine, as well as fieldwork at the Daneros and Sage Plain projects. Source: https://investingnews.com/isoenergy-acquires-toroenergy/

Merck’s (NYSE:MRK) ~$10B acquisition of Verona Pharma (NASDAQ:VRNA) has been granted approval by the High Court of Justice of England and Wales. Under terms, MSD, the trade name of Merck outside the US and Canada, will acquire Verona Pharma for $107 per American Depository Share, with each one accounting for eight Verona ordinary shares. The deal closing is effective Oct. 7. Verona shares will no longer be traded as of market close Monday. Source: https://seekingalpha.com/news/4502146-merck-acquisition-verona-pharma-approved-court

Aware Super, one of Australia’s largest pensions, confirmed plans to merge with smaller rival TelstraSuper to form a A$235 billion ($156 billion) fund. The two pensions have signed a binding Heads of Agreement, and will merge toward the end of the current financial year, according to a statement from Aware Super Tuesday. The funds, which have a combined 1.3 million members, said in July they were exploring a tie-up. Regulators have been pushing funds in Australia’s A$4.3 trillion pension industry to merge and seek economies of scale to offset costs. A report from Mercer in March forecast Australia to have 47 funds by 2029, down from the 89 currently regulated by the Australian Prudential Regulation Authority. Mercer expects that number to drop to about 20 by 2049. Source: https://www.bloomberg.com/news/articles/2025-10-06/two-australian-pensions-confirm-merger-to-form-156-billion-fund

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. The deal will give Halozyme technology capable of turning drug substance into microparticles to enable under-the-skin injections at high concentrations. Called Hypercon, the Elektrofi technology has attracted the likes of argenx, Eli Lilly and Johnson & Johnson. Aside from the $750 million upfront payment, the deal also includes milestone payments valued at $50 million each contingent on three separate product approvals. “This acquisition marks a pivotal step in Halozyme’s evolution,” Halozyme CEO Helen Torley said in an Oct. 1 statement. “With Elektrofi’s Hypercon technology, we are expanding and diversifying our drug delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi’s licensing, royalty revenue business model.” Biologic drugs are often limited by low concentrations, requiring large volumes to deliver effective doses, Torley said during an investor call Wednesday. With Elektrofi’s technology, concentrations of 400 mg/mL to 500 mg/mL, or four to five times higher than standard industry options, can be achieved. This “can make all the difference to enabling more drugs to be able to be delivered in a small volume at home,” she said. Halozyme has been touting the rationale for a strategic M&A deal in the past year or so, and “there could not be a better fit” than Elektrofi, Torley said. Hypercon appears to be highly complementary to Halozyme’s own Enhanze subcutaneous drug delivery technology, which has been utilized in 10 approved products. While Enhanze is a great fit for high-volume products that can be given in a physician’s office or in some cases, in a patient’s home,Hypercon enables drugs to be given in lower volumes and opens up more products to be delivered in homes, Torley said. Growing the number of products that are able to be delivered subcutaneously means more potential partnerships and hence revenues, the Halozyme chief said. Hypercon brings a suite of patents lasting into the 2040s, supporting long-term revenue growth, she noted. By year-end 2026, Halozyme expects that two of Elektrofi’s partner products will have entered the clinic, with potential royalties flowing in as early as 2030. The development and commercial milestone payments to Elektrofi linked to those two products could be worth $275 million, according to Torley. Citing confidentiality agreements, Torley declined to offer more details on the two products other than that they’re both de-risked mechanisms of actions being utilized in existing blockbusters. As for Elektrofi, Halozyme’s knowledge on regulatory approvals for drug delivery technology—and its insights on development and manufacturing requirements—could help accelerate the acquired company’s advancement in the future, Torley added. In what Torley described as another “attractive avenue for commercialization,” Halozyme sees an opportunity to pair Hypercon with its own small-volume autoinjectors, especially in immunology, neurology and other chronic diseases, “where at-home administration is the future of care.” The two companies also have the same business model, relying on licensing milestones and royalty payments without much need for large capital investments in manufacturing infrastructure, clinical development and commercialization. “This capital-efficient approach will allow us to continue to concentrate resources on innovation and on partner success,” Torley said. The two companies’ boards have unanimously approved the transaction, which is expected to close by the end of this year following antitrust reviews. As Torley said on the call, the entire Elektrofi team will join Halozyme post-closing. Although the deal marks the combination of two subcutaneous drug delivery companies, Torley said Halozyme is “confident that this transaction will clear any regulatory review.” Source: https://www.fiercepharma.com/pharma/halozyme-buys-subcutaneous-drug-delivery-peer-elektrofi-900m

SYDNEY, Sept 30 (Reuters) – Australia’s Seven West Media (SWM.AX), opens new tab said it would merge with Southern Cross Media (SXL.AX), opens new tab to create a A$417 million ($273.97 million) metropolitan and regional media group to better compete with global streaming platforms. Seven West shares, controlled by mining and media billionaire Kerry Stokes, were up 7% on Tuesday to A$0.15, while Southern Cross stock was 6.6% higher. Stokes’ Seven Group holds about 40% of Seven West. Under the deal, Seven West shareholders would receive 0.1552 Southern Cross Media shares for each share held. The offer values Seven West shares at A$0.13 each, slightly below the stock’s A$0.14 closing price on Monday. The combined group will be worth A$417 million based on the current market capitalisations of both entities. Southern Cross owns major radio networks and podcast platforms across Australia, while Seven West holds metropolitan and regional television licences. Southern Cross announced the sale of its remaining regional television businesses to Seven West for up to A$24 million in May. MERGER COMBINES RADIO AND TV ASSETS Southern Cross shareholders will own 50.1% of the merged group while Seven West will hold 49.9%, the companies said. “Southern Cross is a much better business with an audio focus and going to buy old world media assets like television and print businesses” said Gabriel Radzyminski, founder of activist investor Sandon Capital which owns 11.2% of Southern Cross. “They are adding different businesses to theportfolio which from a Southern Cross perspective makes it worse.” Sandon is trying to vote the Southern Cross board out at the company’s annual meeting due in November. A Southern Cross spokesperson said the company would engage with all of its investors on the bid, which was backed by both groups’ boards. Free-to-air television in Australia, like all major markets, has faced severe revenue and earnings pressure from streaming giants like Netflix (NFLX.O), opens new tab, Paramount Skydance (PSKY.O), opens new tab and Walt Disney (DIS.N), opens new tab. MERGER TO COUNTER STREAMING GIANTS “We have both (Southern Cross and Seven West) been on the record as being substantial advocates of consolidation,” Southern Cross CEO John Kelly said. “It needs to happen, we need to take the mantle and really fight back against the global behemoths.”The deal requires 75% support from Seven West shareholders at a meeting that will be held in the first quarter of 2026, the companies said, once the deal receives regulatory approvals. Communications and competition regulators, as well as the Australian Securities Exchange, must sign off on the transaction. Seven West said that the board unanimously recommended that its shareholders to vote in favour of the merger, with all directors also pledging to support the deal. Seven West’s current CEO Jeff Howard will lead the combined entity, the broadcaster said. Source: https://www.reuters.com/en/australia-media-groups-unveil-274-million-merger-they-battle-streaming-giants-2025-09-30/